India · Specialty Healthcare Platform · Asset-Light Roll-Up
NASA Hospitals
Building India's premier asset-light specialty healthcare platform. 150 beds across 3 operating hospitals with a proven 12-18 month turnaround playbook. Raising $40M to scale to 1,000 beds in 5 years through a specialty-focused roll-up of distressed mid-market hospitals.
Raising $40M
150 → 1,000 Beds in 5 yr
Target 25–30% ROCE
We don't build hospitals.
We professionalize them.
NASA Hospitals operates a distinctive asset-light specialty healthcare roll-up, targeting 75-100 bed mid-market hospitals with single-specialty focus (Neuro, Spine, Ortho, Critical Care). Corporate-grade outcomes at 20-30% lower cost; exit via IPO or strategic sale at 15–30x EBITDA.
Investment Overview
Raise$40 Million
Current Platform150 beds · 3 hospitals
Target (Year 5)1,000 beds
Target ROCE25–30%
Exit Multiple15x–30x EBITDA
Turnaround Period12–18 months
Patient Cost Discount20–30% below corporate
01
Executive Summary
The Opportunity
NASA Hospitals is building India's premier asset-light specialty healthcare platform. Rather than greenfield hospital construction, NASA acquires and professionalises distressed mid-market hospitals (typically 75-100 beds) and converts them from traditional general-care models into single-specialty focused centres — Neuro, Spine, Ortho, and Critical Care.
The platform has a proven track record: 150 beds across 3 operating hospitals with a 12–18 month turnaround playbook. The $40M raise funds scaling to 1,000 beds over 5 years, targeting 25-30% ROCE and an exit at 15-30× EBITDA via IPO or strategic sale.
The alpha is capturing the arbitrage between corporate hospital pricing and unorganised supply — patients get corporate-grade clinical outcomes at 20-30% lower cost; investors get a capital-efficient platform engineered for superior unit economics and rapid scaling.
02
Performance Metrics
Value Creation · Acquisition · Capital Deployment
Distressed Target
11.8x
FY26 EBITDA entry
Turnaround (12-18mo)
25%+ margins
Post-playbook
Roll-Up (500 beds)
₹27 Cr EBITDA
FY29 Hyderabad platform
IPO Multiple
16-18x
Stabilised exit
Base Case
2.9× MoIC
27% IRR
Prior
3 Hospitals Operating
150 beds across 3 NASA-operated facilities validating the turnaround playbook and specialty-focused model.
Current
$40M Raise — Remedy Close
Flagship Remedy Hospitals Hyderabad acquisition capitalising: 80% stake at ₹55 Cr equity / ₹80 Cr EV.
FY26–FY27
Remedy Turnaround
12-18 month playbook: single-specialty conversion, procurement consolidation, capital restructuring.
FY27–FY29
Hyderabad Roll-Up to 500 Beds
Additional tuck-in acquisitions scaling the Hyderabad platform. FY29 EBITDA target ₹27 Cr.
FY29–FY30
Platform Scaling to 1,000 Beds
Geographic expansion across 2-3 additional tier-1 Indian metros.
FY30+
Exit — IPO or Strategic
IPO at 16-18× stabilised EBITDA or strategic sale. Target 2.8-3.2× MoIC, 26-30% IRR.
$40M Raise — Use of Funds
| Use of Equity (Remedy) | Amount | Purpose |
|---|
| Promoter Buyout | ₹10 Cr | 80% acquisition of Remedy equity |
| Debt Refinancing | ₹15 Cr | Eliminates ₹24.4 Cr debt; saves ₹3.8 Cr annual interest |
| Working Capital | ₹10 Cr | Normalise DSO 90→60 days |
| Capex (CT/ICU) | ₹5 Cr | CT scanner and ICU equipment upgrades |
| NASA Platform Consolidation | ₹15 Cr | Integration of existing 300-bed platform |
| Total Remedy Equity | ₹55 Cr | 80% acquisition complete |
03
Projects
NASA Platform · $40M Raise · Flagship Acquisition
Active · Scaling
NASA Platform
Roll-Up to 1,000 Beds
India · Specialty Healthcare
Capital Raise$40M · Target 25–30% ROCE
Asset-light specialty hospital roll-up. 150 beds across 3 hospitals today, scaling to 1,000 beds in 5 years. 12-18 month turnaround playbook. Single-specialty focus. Exit 15-30x EBITDA via IPO or strategic.
Pipeline · Acquisition
Remedy Hospitals
Hyderabad Acquisition
Hyderabad, India · 150 Beds
Deal Size₹80 Cr EV · 11.8x FY26 EBITDA
80% acquisition at 30% sector discount. Turnaround + roll-up to 500-bed Hyderabad platform by FY29. Target 2.8-3.2x MoIC, 26-30% IRR via IPO exit.
Disclaimer · Investment Materials
Confidentiality & Forward-Looking Statements
This document summarises publicly-releasable project information and does not constitute an offer or solicitation of an offer to buy or sell securities. Forward-looking statements involve risks and uncertainties; actual results may differ materially. Past performance is not indicative of future results.
Confidential sponsor, contact, and financial details are available to authorized investors via the gated Bio & Contact and Business Plan materials.